Table 4.
HPV Test Results at Follow-Up a Compared to Hc2 (Reference).
| HC2, N (col %) b | ||||||
|---|---|---|---|---|---|---|
| HPV Test | Negative | Positive | PABAK (95% CI) |
p-Value c | Agreement % (95% CI) |
|
| Abbott | Negative | 43 (97.7) | 7 (25.9) | 0.78 | 89% | |
| Positive | 1 (2.3) | 20 (74.1) | (0.63, 0.92) | 0.07 | (79.0, 95.0) | |
| Roche | Negative | 28 (100) | 0 | 1.00 | 100% | |
| Positive | 0 | 16 (100) | (1.00, 1.00) | 1.00 | (92.0, 100) | |
| Aptima | Negative | 52 (98.1) | 7 (21.2) | 0.81 | 88% | |
| Positive | 1 (1.9) | 26 (78.8) | (0.69, 0.94) | 0.07 | (80.1, 93.1) | |
| Linear Array | Negative | 36 (100) | 8 (24.2) | 0.77 | 88% | |
| Positive | 0 | 25 (75.8) | (0.62, 0.92) | 0.008 | (78.4, 94.9) | |
| BD Onclarity | Negative | 63 (95.5) | 16 (47.1) | 0.62 | 81% | |
| Positive | 3 (4.6) | 18 (52.9) | (0.47, 0.77) | 0.004 | (71.9, 88.2) | |
| Seegene | Negative | 57 (89.1) | 16 (48.5) | 0.53 | 76% | |
| Positive | 7 (10.9) | 17 (51.5) | (0.36, 0.70) | 0.09 | (66.6, 84.3) | |
a N = 118 patients with first visit at 3–6 months, median f.u. days = 108, (min = 90, max = 179) b Column percent on non-missing counts; c McNemar test; PABAK = Prevalence and Bias adjusted Kappa; 95%CI = 95% Confidence Interval.